Childhood Salivary Gland Tumors Treatment (PDQ®)–Health Professional Version

Changes to This Summary (01/31/2019)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Histology and Molecular Features

Added text to state that in one review, it was estimated that 12% of mammary analog secretory carcinoma (MASC) cases occurred in the pediatric population (cited Khalele as reference 8).

Added text to state that MASC is characterized by an ETV6-NTRK3 fusion (cited Skálová et al. as reference 11).

Treatment of Childhood Salivary Gland Tumors

Added text to state that objective responses have been observed in all reported patients with recurrent NTRK fusion–positive MASCs who were treated with entrectinib or larotrectinib (cited 2017 Drilon et al. and 2018 Drilon et al. as references 7 and 8, respectively).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Special Considerations for the Treatment of Children With Cancer

Next section >
About This PDQ Summary